A Clinical Study of  HB sAg‐Activated Dendritic Cells and Cytokine‐Induced Killer Cells During the Treatment for Chronic Hepatitis B | Zendy

Ma Y.J. | Zendy; He M. | Zendy; Han J.A. | Zendy; Yang L. | Zendy; Ji X.Y. | Zendy

Premium

A Clinical Study of HB sAg‐Activated Dendritic Cells and Cytokine‐Induced Killer Cells During the Treatment for Chronic Hepatitis B

Author(s) -

Ma Y.J.,

He M.,

Han J.A.,

Yang L.,

Ji X.Y.

Publication year - 2013

Publication title -

scandinavian journal of immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.934

H-Index - 88

eISSN - 1365-3083

pISSN - 0300-9475

DOI - 10.1111/sji.12097

Subject(s) - immunology , medicine , cytokine induced killer cell , viral load , immunotherapy , cytokine , immune system , hepatitis b , viral hepatitis , virus , cd3 , cd8

We aim to study the therapeutic effects of HB sAg‐activated DC s and cytokine‐induced killer ( CIK ) cells as adoptive immunotherapy in patients with Chronic Hepatitis B ( CHB ). Autologous HB sAg‐activated DC – CIK cells were infused into patients with CHB to evaluate their effect on HBV ‐ DNA , HB sAg, ALT , etc. The viral load in the treatment group decreased significantly ( P < 0.001), while that in the control group did not decrease ( P > 0.05). Twenty‐one patients (63.6% efficiency) in the treatment group had a viral response (≥2 log decrease in viral load), while four patients (14.8% efficiency) from the control group had a viral response. There were significant differences in the viral responses of the two groups (the control group 63.6% versus the control group 14.8%, P < 0.001). We concluded that the immunity was enhanced after HB sAg activation in DC s and CIK cells. Reinfusion of autologous HB sAg‐activated DC – CIK cells inhibited HBV proliferation in 21 of 33 (63.6%) patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research